Patent classifications
C07D215/42
Activators and therapeutic applications thereof
The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.
3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:
##STR00001##
The compounds are useful for treating inflammatory and autoimmune diseases.
Heterocyclic compound
The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).
Heterocyclic compound
The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).
Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof
The present invention relates to quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), the preparation thereof and uses thereof. ##STR00001##
Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof
The present invention relates to quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), the preparation thereof and uses thereof. ##STR00001##
TETRAHYDROQUINOLINE (THQ) COUMPOUNDS
The present invention relates to new tetrahydroquinoline (THQ) compounds and new methods for synthetizing such compounds.
The present invention relates to the applications thereof, in particular in therapeutic treatment.
The present invention relates in particular to compound having the following structure:
##STR00001##
wherein R, R, R.sub.A, Nu, R1, R2, R3, and R4 are each independently an atom or a chemical group of atoms.
TETRAHYDROQUINOLINE (THQ) COUMPOUNDS
The present invention relates to new tetrahydroquinoline (THQ) compounds and new methods for synthetizing such compounds.
The present invention relates to the applications thereof, in particular in therapeutic treatment.
The present invention relates in particular to compound having the following structure:
##STR00001##
wherein R, R, R.sub.A, Nu, R1, R2, R3, and R4 are each independently an atom or a chemical group of atoms.
QUINOLINE COMPOUND SUSTAINED-RELEASE TABLET AND PREPARATION METHOD THEREFOR
This patent document provides a sustained-release formulation comprising 1-40 parts of a quinoline compound, 100-300 parts of a filler, 50-200 parts of a sustained-release material and optionally 0.5-4 parts of a lubricant. Also provided are methods of treating diseases with the sustained-release formulation.
COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS
The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessels. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.